Is Cell Point overvalued or undervalued?

As of 16 October 2025, the valuation grade for Cell Point has moved from expensive to fair. The company is currently fairly valued based on its financial metrics. Key ratios include a PE ratio of 91.92, an EV to EBITDA of 9.93, and a Price to Book Value of 0.46.
When compared to peers, Cell Point's PE ratio is significantly lower than that of Elitecon International, which stands at 377.47, indicating that Cell Point is more reasonably priced despite its high PE ratio. Additionally, Optiemus Infra, also rated fair, has a PE ratio of 85.49, suggesting that Cell Point is competitive within its valuation range. Notably, the company's stock has underperformed relative to the Sensex, with a year-to-date return of -31.96% compared to the Sensex's 8.21%, reinforcing the notion that Cell Point's current valuation may be more attractive than its recent performance suggests.